![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Hattan D.
Publisher: Academic Press
ISSN: 0273-2300
Source: Regulatory Toxicology and Pharmacology, Vol.24, Iss.3, 1996-12, pp. : 232-235
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
More funds requested for US FDA's safety initiatives
Reactions Weekly, Vol. 1, Iss. 1207, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
The US Public Citizen group has requested that the FDA remove leflunomide [`Arava']
Inpharma, Vol. 1, Iss. 1334, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
FDA grants priority review for prasugrel
Inpharma, Vol. 1, Iss. 1627, 2008-01 ,pp. :